Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD
NCT00446654
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
43
Enrollment
INDUSTRY
Sponsor class
Conditions
Age Related Macular Degeneration
Interventions
DRUG:
CGC-11047
Sponsor
Progen Pharmaceuticals